<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02029196</url>
  </required_header>
  <id_info>
    <org_study_id>ITG EVP G1 S2</org_study_id>
    <nct_id>NCT02029196</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety Profile of an e-Vapour Product</brief_title>
  <official_title>A Randomised, Parallel Group, Multi-centre Study to Evaluate the Safety Profile of the ITG EVP G1 Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial Tobacco Group PLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial Tobacco Group PLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Electronic Vapour Products (EVPs) is a relatively new class of consumer products that are
      otherwise known as electronic cigarettes or electronic nicotine delivery devices/systems.
      These may look like conventional cigarettes but do not contain tobacco.

      The 'vapour' produced by such devices typically consists of humectants (propylene glycol or
      glycerol), nicotine, water, and flavours.

      This trial is to evaluate the safety of an e-vapour product.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Frequency of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exhaled Carbon Monoxide</measure>
    <time_frame>12 weeks</time_frame>
    <description>Level of exhaled carbon monoxide at Week 12</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>e-vapour product (EVP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>E-vapour product</intervention_name>
    <description>Smokers of conventional cigarettes who switch to use an e-vapour product.</description>
    <arm_group_label>e-vapour product (EVP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional cigarette</intervention_name>
    <description>Smokers of conventional cigarettes who continue smoking conventional cigarettes.</description>
    <arm_group_label>Conventional cigarette (CC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) of 18-35kg/m2

          -  Subjects must be established smokers

          -  Subjects must have smoked five to 30 cigarettes per day for at least one year

        Exclusion Criteria:

          -  Subjects who have used nicotine replacement therapy within 14 days of the screening

          -  Subjects who have donated blood within 12 months preceding study

          -  Subjects with relevant illness history

          -  Subjects positive for hepatitis or Human Immunodeficiency Virus (HIV)

          -  Subjects with history of drug or alcohol abuse

          -  Subjects with lung function test or vital signs considered unsuitable

          -  Subjects who are trying to stop smoking

          -  Female subjects who are pregnant, or unwilling to use acceptable contraceptive method
             for the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Bush, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit, Springfield House, Hyde Street, Leeds LS2 9LH, UK</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Girish Sharma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Simbec Research, Merthyr Tydfil, CF48 4DR, UK</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS2 9HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Simbec Research</name>
      <address>
        <city>Merthyr Tydfil</city>
        <state>Wales</state>
        <zip>CF48 4DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2013</study_first_submitted>
  <study_first_submitted_qc>January 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2014</study_first_posted>
  <results_first_submitted>November 23, 2016</results_first_submitted>
  <results_first_submitted_qc>January 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 21, 2017</results_first_posted>
  <last_update_submitted>January 31, 2017</last_update_submitted>
  <last_update_submitted_qc>January 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>E-vapour Product (EVP)</title>
          <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
        </group>
        <group group_id="P2">
          <title>Conventional Cigarette (CC)</title>
          <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="306"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>E-vapour Product (EVP)</title>
          <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
        </group>
        <group group_id="B2">
          <title>Conventional Cigarette (CC)</title>
          <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="306"/>
            <count group_id="B2" value="102"/>
            <count group_id="B3" value="408"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="10.6"/>
                    <measurement group_id="B2" value="35.1" spread="10.6"/>
                    <measurement group_id="B3" value="34.3" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="182"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Exhaled Carbon Monoxide (eCO)</title>
          <units>parts per million (ppm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.8" spread="6.3"/>
                    <measurement group_id="B2" value="16.7" spread="7.3"/>
                    <measurement group_id="B3" value="16.0" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>Frequency of adverse events</description>
        <time_frame>12 weeks</time_frame>
        <population>All subjects who used the study product at least once.</population>
        <group_list>
          <group group_id="O1">
            <title>E-vapour Product (EVP)</title>
            <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Frequency of adverse events</description>
          <population>All subjects who used the study product at least once.</population>
          <units>percentage of adverse events</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" lower_limit="1.55" upper_limit="1.65"/>
                    <measurement group_id="O2" value="0.79" lower_limit="0.66" upper_limit="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exhaled Carbon Monoxide</title>
        <description>Level of exhaled carbon monoxide at Week 12</description>
        <time_frame>12 weeks</time_frame>
        <population>Measure performed on subjects who completed the 12-week study (286 in the e-vapour product arm and 100 in the conventional cigarette arm).</population>
        <group_list>
          <group group_id="O1">
            <title>E-vapour Product (EVP)</title>
            <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
          </group>
          <group group_id="O2">
            <title>Conventional Cigarette (CC)</title>
            <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
          </group>
        </group_list>
        <measure>
          <title>Exhaled Carbon Monoxide</title>
          <description>Level of exhaled carbon monoxide at Week 12</description>
          <population>Measure performed on subjects who completed the 12-week study (286 in the e-vapour product arm and 100 in the conventional cigarette arm).</population>
          <units>parts per million (ppm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.99" spread="6.33"/>
                    <measurement group_id="O2" value="23.1" spread="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>E-vapour Product (EVP)</title>
          <description>Subjects who switch from using conventional cigarettes to using an e-vapour product (EVP).</description>
        </group>
        <group group_id="E2">
          <title>Conventional Cigarette (CC)</title>
          <description>Subjects who continue smoking their usual conventional cigarette (CC) brand.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>Sudden death due to severe cardiac arrhythmia as confirmed by post mortem</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <description>Right lobar pneumonia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Wound</sub_title>
                <description>Puncture wound, left hand, first finger</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="306"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="271" subjects_at_risk="306"/>
                <counts group_id="E2" subjects_affected="74" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="36" subjects_affected="33" subjects_at_risk="306"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="34" subjects_at_risk="306"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="306"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="372" subjects_affected="145" subjects_at_risk="306"/>
                <counts group_id="E2" events="72" subjects_affected="34" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Desire to smoke</sub_title>
                <counts group_id="E1" events="86" subjects_affected="84" subjects_at_risk="306"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" events="119" subjects_affected="85" subjects_at_risk="306"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="62" subjects_affected="52" subjects_at_risk="306"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Ana Cravo</name_or_title>
      <organization>Fontem Ventures</organization>
      <phone>+441173322528</phone>
      <email>AnaMaria.Cravo@fontemventures.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

